BriaCell Therapeutics Corp. BCTXF Archives - Page 2 of 6

TuesdayFeb 26, 2019 9:51 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Director to Invest C$500,000 in Private Placement Financing

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced a non-brokered private placement financing of 5,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of C$500,000. According to the update, recently-appointed BriaCell Director Jamieson Bondarenko will purchase the 5,000,000 common shares and, upon closing, will have beneficial ownership of an aggregate of 23,070,500 or 13.7 percent of the company’s issued and outstanding common shares. BriaCell intends to use net proceeds to finance its Phase IIa combination study of Bria-IMT(TM) with KEYTRUDA® (by Merck & Co., Inc.)…

FridayFeb 22, 2019 11:45 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Announce Breast Cancer Immunotherapy Findings at Key Oncology Conferences

BriaCell Therapeutics Corp. will reveal important information about Bria-IMT and Bria-OTS at two leading conferences – the ASCO-SITC Clinical Immuno-Oncology Symposium and the American Association of Cancer Research’s annual meeting New information will also be made available about the company’s HLA-identification test, BriaDX, which is aimed at identifying patients most likely to benefit from Bria-IMT In addition, BriaCell founder and director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in France BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company with a focus on immune-oncology, is expected to announce findings pertaining…

TuesdayFeb 19, 2019 10:26 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Targets Advanced Breast Cancer with Proprietary Immunotherapy

Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile Cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company that’s currently focused on the development of targeted immunotherapy solutions for advanced breast cancer patients, has, to date, demonstrated excellent results with Bria-IMT in several clinical trials.…

TuesdayFeb 19, 2019 10:16 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Clinical and Scientific Findings at Key Oncology Conferences

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California from February 28 to March 2, 2019. The poster will highlight findings related to the mechanism of action of BriaCell’s lead candidate, Bria-IMT(TM), as well as BriaDX(TM), the Bria-IMT(TM) companion diagnostic test and Bria-OTS(TM), the company’s off-the-shelf personalized immunotherapy. In addition, BriaCell Founder and Director…

WednesdayFeb 13, 2019 3:13 pm

QualityStocksNewsBreaks – Newly Appointed Board of Directors Member Increases Beneficial Ownership of BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT)

On February 12, 2019 Jamieson Bondarenko, a recently appointed member of BriaCell Therapeutics’ (OTCQB: BCTXF) (TSX.V: BCT) Board of Directors, acquired 2,000,000 common shares of the company through the facilities of the TSX Venture Exchange at a price of $0.0975 per share for a total purchase price of $195,000. Bondarenko previously held 16,070,500 common shares of the company, representing about 9.8 percent of BriaCell’s issued and outstanding common shares. Following the acquisition, Bondarenko now has beneficial ownership of 18,070,500 common shares, representing approximately 11 percent of the company’s issued and outstanding common shares. To view the full press release, visit…

TuesdayFeb 12, 2019 9:11 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints New Member to Board of Directors

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company's Board of Directors. Through his merchant capital company, JGRNT Capital Corp., Bondarenko currently offers strategic capital markets and corporate development advice to early-stage life sciences companies. He has also served as Principal, Managing Director of Equity Capital Markets at Eight Capital and Equity Capital Markets as well as Investment Banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. “Jamieson brings extensive capital markets experience to BriaCell,”…

MondayFeb 11, 2019 11:50 am

Immunotherapy is the ‘Next Era’ of Cancer Treatment and BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is Taking Steps Forward in this Field

Multiple breakthroughs in the field of onco-immunology are expected over the next 20 years BriaCell Therapeutics Corp. is a frontrunner in this area, as it has already established proof of concept for its Bria-IMT solution for advanced breast cancer patients The company is also developing Bria-OTS, a personalized off-the-shelf solution, that will be much easier and less costly to manufacture than comparable personalized immunotherapies According to a report published in the British Society of Immunology, a new era has begun in the battle against cancer, as the development of immunotherapies for malignancies will take cancer treatments to a whole new…

FridayFeb 08, 2019 12:08 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing Novel Treatment Options for Cancer Patients in Booming Market Forecasted to Reach $145 Billion by 2022

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is currently developing immunotherapy solutions demonstrated to be highly effective and well tolerated by patients. The market share for immunotherapy treatments for breast cancer as well as other malignancies is forecasted to surge in the coming years. An article discussing the company reads, “Several studies indicate that the incidence of breast cancer is expected to increase in the next decade (http://ibn.fm/XR9CX). U.S. breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000 in 2030, an increase of over 50 percent. The proportion of cases diagnosed…

FridayFeb 01, 2019 3:16 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Development of Personalized Immunotherapy Solution for Cancer Patients

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is advancing the development of a cost-saving solution for cancer patients. An article discussing the company reads, “BriaCell’s development of Bria-OTS, a personalized immunotherapy solution that matches the needs of the patient without a specialized manufacturing process, is designed to mitigate some of those worries. This personalized treatment is expected to be safe and highly effective while avoiding the high costs of creating personalized treatments for advanced cancer patients. In addition, Bria-OTS is created to produce a selective immune response that’s tailored to the specific needs of the…

FridayFeb 01, 2019 10:34 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Personalized Immunotherapy Technology Targeting Advanced Breast Cancer Patients

Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites New formulation to accommodate higher patient volumes at reduced per-dose costs Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast cancer patients The global cancer immunotherapy market is expected to be valued at nearly $125 billion by the end of 2024 Breast cancer remains one of the most commonly diagnosed cancers among women globally, with 2.1 million cases expected in 2018 Battling a cancer prognosis is often referred to as “fighting the good fight,” but it’s a tough, uphill battle…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF